X

Trial Profile

A phase Ib/IIa clinical trial in pancreatic cancer in combination with chemotherapy and Zalifrelimab

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NLM-001 (Primary) ; Zalifrelimab (Primary) ; Antineoplastics
Indications Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Nelum

Most Recent Events

01 Feb 2021 New trial record
26 Jan 2021 According to an Agenus media release, the company has entered into a clinical collaboration with Nelum Corp. to evaluate the safety and efficacy of zalifrelimab in combination with NLM-001, and chemotherapy for first-line advanced pancreatic cancer. The trial is set to begin enrolling in 1H21.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com